Medical Device Advances in the Treatment of Glioblastoma
Overview
Authors
Affiliations
Despite decades of research and the growing emergence of new treatment modalities, Glioblastoma (GBM) frustratingly remains an incurable brain cancer with largely stagnant 5-year survival outcomes of around 5%. Historically, a significant challenge has been the effective delivery of anti-cancer treatment. This review aims to summarize key innovations in the field of medical devices, developed either to improve the delivery of existing treatments, for example that of chemo-radiotherapy, or provide novel treatments using devices, such as sonodynamic therapy, thermotherapy and electric field therapy. It will highlight current as well as emerging device technologies, non-invasive versus invasive approaches, and by doing so provide a detailed summary of evidence from clinical studies and trials undertaken to date. Potential limitations and current challenges are discussed whilst also highlighting the exciting potential of this developing field. It is hoped that this review will serve as a useful primer for clinicians, scientists, and engineers in the field, united by a shared goal to translate medical device innovations to help improve treatment outcomes for patients with this devastating disease.
Dhiman A, Rana D, Benival D, Garkhal K Ther Deliv. 2024; 16(1):87-115.
PMID: 39445563 PMC: 11703381. DOI: 10.1080/20415990.2024.2415281.
Emerging and Biological Concepts in Pediatric High-Grade Gliomas.
Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V Cells. 2024; 13(17.
PMID: 39273062 PMC: 11394548. DOI: 10.3390/cells13171492.
Ma J, Singh S, Li M, Seelig D, Molnar G, Wong E Neurooncol Adv. 2024; 6(1):vdae121.
PMID: 39156619 PMC: 11327618. DOI: 10.1093/noajnl/vdae121.
Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review.
Rodriguez B, Rivera D, Zhang J, Brown C, Young T, Williams T Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543086 PMC: 10976112. DOI: 10.3390/ph17030300.
Witusik-Perkowska M, Glowacka P, Pieczonka A, Swiderska E, Pudlarz A, Rachwalski M Cells. 2023; 12(14).
PMID: 37508570 PMC: 10378024. DOI: 10.3390/cells12141906.